Boudreau Philip P 4

What Happened
Philip P. Boudreau, EVP and Chief Financial Officer of Abbott Laboratories (ABT), received a grant of performance-based restricted stock on February 24, 2026. The filing shows two award entries totaling 143,410 shares: 27,997 shares reported as a direct award and 115,413 shares reported as a derivative award. Both were reported at $0.00 (awarded, not purchased).

Key Details

• Transaction date: February 24, 2026; Form 4 filed February 26, 2026 (appears timely).
• Awards: 27,997 shares (direct) and 115,413 shares (derivative), both with acquisition price $0.00 (total value not shown in filing).
• Post-transaction holdings: The filing references a balance in the Abbott Laboratories Stock Retirement Trust as of Feb 24, 2026 (Footnote F2); the filing excerpt provided does not list a total shareholding for Boudreau.
• Footnote F1: These shares are performance-based restricted stock under Abbott’s 2017 Incentive Stock Program, with a 3-year performance term and no more than 1/3 vesting in any year upon meeting a minimum return-on-equity target; the award allows withholding of shares for taxes.
• Footnote F3: The filing also describes an employee stock option grant with exercisability in annual increments of 38,471 shares on Feb 24 of 2027, 2028 and 2029; no exercise or sale occurred in this report.
• Transaction code: A = Award/Grant (not a purchase or sale).

Context

• Awards are compensation, not open-market purchases, so they reflect company pay practices rather than an immediate market sentiment signal.
• The derivative/contingent portion means vesting depends on future performance targets (ROE) over the three-year term. Tax-withholding via share withholding is allowed under the award terms.